Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000586519 | SCV000698526 | pathogenic | Cystinosis | 2017-07-05 | criteria provided, single submitter | clinical testing | Variant summary: The variant results in the deletion of a 23 nucleotides leading to a termination codon at position 288 of CTNS. The variant was present at a low frequency in the large and broad cohorts of the ExAC project (3/121,076 chromosomes) while it was observed in multiple CTNS patients in the literature. Considering all evidence, the variant was classified as pathogenic. |
Labcorp Genetics |
RCV002530936 | SCV000961592 | pathogenic | Ocular cystinosis; Juvenile nephropathic cystinosis; Inborn genetic diseases | 2024-12-02 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gly258Serfs*30) in the CTNS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CTNS are known to be pathogenic (PMID: 9537412, 27102039). This variant is present in population databases (rs759623796, gnomAD 0.02%). This premature translational stop signal has been observed in individuals with cystinosis (PMID: 10556299, 26266097). This variant is also known as c.1109_1131del23. ClinVar contains an entry for this variant (Variation ID: 496276). For these reasons, this variant has been classified as Pathogenic. |
Centogene AG - |
RCV000586519 | SCV001424396 | pathogenic | Cystinosis | criteria provided, single submitter | clinical testing | ||
Johns Hopkins Genomics, |
RCV000984254 | SCV001573147 | pathogenic | Nephropathic cystinosis | 2021-04-26 | criteria provided, single submitter | clinical testing | This 23 bp deletion in CTNS has been previously reported in individuals with nephropathic cystinosis. This CTNS variant (rs759623796) is rare (<0.1%) in a large population dataset (gnomAD: 7/251296 total alleles; 0.003%; no homozygotes) and there is an entry in ClinVar. This frameshift variant results in a premature stop codon in exon 11 likely leading to nonsense-mediated decay and lack of protein production. We consider this variant to be pathogenic. |
Revvity Omics, |
RCV003139887 | SCV003819373 | pathogenic | not provided | 2021-12-02 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000984254 | SCV004215218 | pathogenic | Nephropathic cystinosis | 2022-12-25 | criteria provided, single submitter | clinical testing | |
Genomic Medicine Center of Excellence, |
RCV000984254 | SCV004806437 | pathogenic | Nephropathic cystinosis | 2024-03-25 | criteria provided, single submitter | clinical testing | |
Neuberg Centre For Genomic Medicine, |
RCV000984254 | SCV005329277 | pathogenic | Nephropathic cystinosis | 2023-05-20 | criteria provided, single submitter | clinical testing | The observed frameshift c.771_793del (p.Gly258SerfsTer30) variant in CTNS gene has been reported in homozygous state in individual(s) affected with cystinosis (Chkioua L et al., 2015; Ghazi F, et. al., 2017). The p.Gly258SerfsTer30 variant is present with allele frequency 0.003% in gnomAD Exomes database. This variant has been submitted to the ClinVar database as Likely Pathogenic / Pathogenic (multiple submitters). This variant causes a frameshift starting with codon Glycine 258, changes this amino acid to Serine residue, and creates a premature Stop codon at position 30 of the new reading frame, denoted p.Gly258SerfsTer30. This variant is predicted to cause loss of normal protein function through protein truncation. Loss-of-function variants in CTNS are known to be pathogenic (Elmonem MA, et. al., 2016). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005091542 | SCV005641930 | pathogenic | Ocular cystinosis; Juvenile nephropathic cystinosis; Nephropathic cystinosis | 2024-01-24 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000984254 | SCV001132377 | likely pathogenic | Nephropathic cystinosis | 2014-08-16 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000586519 | SCV002093236 | pathogenic | Cystinosis | 2021-01-26 | no assertion criteria provided | clinical testing |